Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase NA 3Phase 2 3Phase 3 2Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Cancer Female 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9Trastuzumab 8anlotinib 7Injections 7Rituximab 6venetoclax 5atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Azacitidine 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × pegylated granulocyte colony-stimulating factor × Clear all
NCT04554056 2022-12-02

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2/3 Completed
586 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡